Atossa Therapeutics’ (ATOS) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Atossa Therapeutics (NASDAQ:ATOS) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $7.00 price target on the stock.

Other analysts have also recently issued research reports about the company. StockNews.com cut Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, November 18th. Ascendiant Capital Markets upped their target price on Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research report on Monday, December 9th.

Atossa Therapeutics Trading Down 2.6 %

Atossa Therapeutics stock opened at $1.12 on Thursday. The company has a market capitalization of $140.90 million, a P/E ratio of -5.09 and a beta of 1.21. Atossa Therapeutics has a 1-year low of $0.70 and a 1-year high of $2.31. The firm’s fifty day simple moving average is $1.35 and its 200-day simple moving average is $1.33.

Institutional Investors Weigh In On Atossa Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. XTX Topco Ltd bought a new stake in Atossa Therapeutics during the 2nd quarter valued at approximately $29,000. Intech Investment Management LLC bought a new stake in shares of Atossa Therapeutics in the third quarter valued at approximately $29,000. SG Americas Securities LLC grew its stake in shares of Atossa Therapeutics by 254.3% in the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after acquiring an additional 30,037 shares during the last quarter. Cetera Advisors LLC bought a new position in Atossa Therapeutics during the first quarter worth $72,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Atossa Therapeutics during the 3rd quarter valued at $75,000. 12.74% of the stock is owned by institutional investors and hedge funds.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.